IBBvsXBI

iShares Biotechnology ETF or State Street SPDR S&P Biotech ETF, side by side from their own SEC filings. 40% of their stock holdings are the same at the same weight, across 113 stocks in both. XBI costs 0.35% a year against 0.44% for IBB, $9 a year less on $10,000. Over the last twelve months IBB returned +50.6% and XBI +91.7%.

40%of the two portfolios is the same stocks at the same weight
IBB74% in stocks the other holds too
XBI81% in stocks the other holds too
stocks in bothstocks only in that fundbonds, cash and unmatched shares

The two funds

From each fund's latest N-PORT filing and its prospectus.

IBBXBIYearly cost0.44%0.35%Net assets$9.1B$10.7BPositions252161Last 12 months+50.6%+91.7%3 years, a year+14.7%+24.1%5 years, a year+3.3%+3.3%Largest holdingBlackRock 12.0%State 5.9%Main sectorHealthcare 97%Healthcare 94%Holdings as ofJun 30, 2026Jun 30, 2026

Returns are total returns with dividends reinvested, from the funds’ own monthly figures; “(price)” marks a fund whose filing record is younger than a year, whose twelve months are its price change. The stronger figure in each row is set in bold. Past returns say what happened, not what will.

Growth of $100

Both funds from July 2019, the first month both report, dividends reinvested.

IBB$177XBI$182
July 2019June 2026

More comparisons

From each fund’s Form N-PORT (IBB: June 2026, XBI: June 2026) and prospectus, via the SEC’s public data sets. Overlap counts only the stocks we can match to a listing: stock by stock, the smaller of the two weights, added up.